Abliva continues to solidify its position as a leader in developing treatments for mitochondrial disease. During Q3 2024, the biotech company reached a milestone with the positive interim analysis of its FALCON trial, evaluating the drug candidate KL1333 as a potential treatment for primary mitochondrial disease.
Read the article about Abliva at biostock.se:
https://www.biostock.se/en/2024/12/from-mutation-to-solution-abliva-gains-ground/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/
